Therapy Areas: Central Nervous System
Alkermes reports departure of COO Jim Robinson
9 April 2019 -

Biopharmaceutical company Alkermes plc (Nasdaq:ALKS) revealed on Monday the planned resignation of Jim Robinson with effect from 19 April 2019 for personal reasons.

Currently, Robinson serves as the president and chief operating officer in the company.

Alkermes develops medicines for the treatment of central nervous system (CNS) diseases.It has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction, multiple sclerosis and oncology.

Headquartered in Dublin, Ireland, the company has an R&D centre in Waltham, Massachusetts, a research and manufacturing facility in Athlone, Ireland and a manufacturing facility in Wilmington, Ohio.

Login
Username:

Password: